About Dr. Shen Kunwei
Dr. Shen Kunwei (沈坤炜) is one of China's most distinguished breast surgeons and a nationally recognized authority on breast cancer surgery, oncoplastic reconstruction, and multidisciplinary breast cancer management. He serves as Director of the Department of Breast Surgery at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and holds the title of Chief Physician and Professor.
Over a career spanning more than three decades, Dr. Shen has established Ruijin Hospital's Breast Surgery Department as one of the premier breast cancer centers in China. He is particularly renowned for his expertise in breast-conserving surgery, oncoplastic techniques, and sentinel lymph node biopsy — areas where his contributions have shaped national clinical guidelines and influenced breast surgery practice across Asia. His commitment to combining oncological safety with aesthetic outcomes has made him a sought-after surgeon for patients who prioritize both cancer control and quality of life.
International patients with breast cancer — whether seeking primary surgical treatment, a second opinion on surgical planning, or access to the latest neoadjuvant and adjuvant therapy protocols — consistently identify Dr. Shen as one of China's top breast cancer specialists.
Professional Positions and Affiliations
- Director, Department of Breast Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Chairman, Breast Cancer Committee, Chinese Anti-Cancer Association (CACA)
- Vice President, Chinese Society of Breast Surgery
- Editorial Board Member: Breast Cancer Research and Treatment, Annals of Surgical Oncology, Chinese Journal of Surgery
- Member, European Society of Breast Cancer Specialists (EUSOMA)
- Member, American Society of Breast Surgeons (ASBrS)
- Principal Investigator, multiple national and international multicenter clinical trials in breast cancer surgery and systemic therapy
Specialties and Clinical Expertise
Dr. Shen's clinical practice covers the full spectrum of breast disease, with particular depth in breast cancer surgery and oncoplastic reconstruction. His approach integrates the latest surgical techniques with multidisciplinary systemic therapy planning to deliver optimal oncological and cosmetic outcomes.
- Breast-Conserving Surgery (BCS) — lumpectomy and wide local excision with oncoplastic volume displacement and replacement techniques; margin assessment with intraoperative frozen section and cavity shaving
- Mastectomy and Reconstruction — skin-sparing mastectomy (SSM), nipple-sparing mastectomy (NSM), and total mastectomy; immediate and delayed reconstruction with implants, tissue expanders, and autologous flaps (TRAM, DIEP, latissimus dorsi)
- Sentinel Lymph Node Biopsy (SLNB) — dual-tracer technique (radioisotope and blue dye); omission of axillary dissection in sentinel node-negative and selected sentinel node-positive patients
- Axillary Lymph Node Dissection (ALND) — level I-III dissection for node-positive disease; nerve-sparing techniques to minimize lymphedema and sensory loss
- Oncoplastic Breast Surgery — volume displacement (reduction mammoplasty, mastopexy) and volume replacement (local and regional flaps) techniques for large tumor-to-breast ratio cases
- Neoadjuvant Therapy and Surgery — surgical planning after neoadjuvant chemotherapy or endocrine therapy; pathological complete response assessment and de-escalation of axillary surgery
- Hereditary Breast Cancer — BRCA1/2 and other high-risk gene mutation carriers; risk-reducing mastectomy and surveillance protocols
- Male Breast Cancer — surgical and systemic management of this rare but important condition
- Benign Breast Disease — fibroadenoma, phyllodes tumor, breast cysts, and nipple discharge evaluation
Academic and Research Contributions
Dr. Shen Kunwei has published over 240 peer-reviewed papers in leading international breast cancer journals, with a particular focus on the optimization of breast-conserving surgery, sentinel lymph node biopsy techniques, and the integration of neoadjuvant therapy with surgical planning. His research on the safety and oncological outcomes of nipple-sparing mastectomy in Chinese patients has been widely cited and has contributed to the adoption of this technique as standard practice across China.
He has led or co-led numerous multicenter trials evaluating de-escalation of axillary surgery after neoadjuvant chemotherapy, oncoplastic techniques for breast conservation in Asian patients (who typically have smaller breast volumes than Western patients, making conservation more technically challenging), and the integration of CDK4/6 inhibitors and PARP inhibitors into the perioperative management of breast cancer.
Dr. Shen chairs the Breast Cancer Committee of the Chinese Anti-Cancer Association (CACA) and has been the lead author on multiple editions of China's national breast cancer surgical guidelines. He is a regular invited speaker at the San Antonio Breast Cancer Symposium (SABCS), the European Breast Cancer Conference (EBCC), and the St. Gallen International Breast Cancer Conference.
Approach to Patient Care
Dr. Shen is known for his patient-centered approach to breast cancer surgery, taking particular care to discuss all surgical options — including breast-conserving approaches, reconstruction choices, and the implications of genetic testing — with each patient before proceeding. He leads a multidisciplinary breast cancer team that brings together breast surgeons, medical oncologists, radiation oncologists, plastic surgeons, pathologists, and radiologists to develop comprehensive, individualized treatment plans.
For international patients — many of whom arrive with prior imaging, biopsy results, and treatment recommendations from overseas institutions — Dr. Shen takes particular care to review all available data before forming an independent surgical opinion. His familiarity with international guidelines (NCCN, ESMO, St. Gallen) makes him an ideal consultant for patients seeking a second opinion on surgical planning or access to techniques not available in their home country.
Hospital: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Ruijin Hospital is one of China's most prestigious academic medical centers. The Department of Breast Surgery at Ruijin is a National Key Clinical Specialty and one of the highest-volume breast cancer centers in China, managing over 2,000 new breast cancer cases annually. The department operates:
- A dedicated Breast Cancer Multidisciplinary Team (MDT) meeting weekly, integrating surgery, medical oncology, radiation oncology, plastic surgery, and pathology
- A Genetic Counseling and High-Risk Clinic for BRCA and other hereditary breast cancer gene mutation carriers
- An Oncoplastic Surgery Program with dedicated plastic surgery collaboration for immediate reconstruction
- A Neoadjuvant Therapy Clinic for pre-surgical systemic treatment planning and response assessment
- A Clinical Trials Unit running multiple Phase II-III studies in breast cancer surgery and systemic therapy
Why International Patients Choose Dr. Shen Kunwei
- China's leading breast cancer surgeon — Chairman of CACA Breast Cancer Committee and national guideline author
- Oncoplastic expertise — combining cancer control with aesthetic outcomes, particularly important for Asian patients with smaller breast volumes
- Nipple-sparing mastectomy pioneer — one of China's most experienced surgeons in this body-image-preserving technique
- NCCN/ESMO-aligned practice — familiar with international guidelines, ideal for patients from Western healthcare systems
- High-volume center — 2,000+ new breast cancer cases annually translates to unmatched surgical expertise
- Second opinion authority — regularly reviews overseas imaging and surgical plans for international patients
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Ruijin Hospital, 197 Ruijin Er Road, Huangpu District, Shanghai
- Appointment Lead Time: 2–3 weeks for new patients; urgent cases may be expedited through CMCS
- Consultation Format: In-person consultation; remote pre-consultation imaging and pathology review available through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Medical Records: CMCS provides full translation of overseas imaging, pathology, and treatment records into Chinese prior to consultation
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking consultation or treatment with Dr. Shen Kunwei at Ruijin Hospital. Our services include:
- Priority appointment booking and scheduling coordination
- Medical record, imaging, and pathology report translation (English ↔ Chinese)
- Remote pre-consultation imaging and pathology review facilitation
- On-site interpretation during consultations and surgical procedures
- Accommodation coordination near Ruijin Hospital
- Insurance liaison and billing support
- Post-surgical follow-up coordination with your home country oncologist
- Clinical trial eligibility assessment for breast cancer studies
📧 Contact us: contract@medicalsh.com
💬 WeChat: gezhanglao
🌐 medicalsh.com
0 commenti